Overview of key financial metrics and trend context (USD, unless noted):
- Revenue: Not reported for QQ2 2025; effectively nil in the period. Gross profit not reported as revenue is absent.
- EBITDA: -$1,345,000; Operating loss: -$1,358,000; Net income: -$1,362,000; EPS: -$0.40. QoQ changes show a sharp swing in operating metrics (QoQ operating income down -41.16%; YoY operating income up 53.20% but still negative; Net income YoY up 53.13% but remains negative with -$1.362 million).
- Revenue/Profitability commentary: With no reported revenue, all profitability metrics are driven by R&D and SG&A spend. The negative trajectory highlights ongoing investment in AL001 and infrastructure ahead of potential product approvals.
- Cash flow and liquidity: Net cash used in operating activities: -$3,400,101. Free cash flow: -$3,310,101. Net cash from financing activities: +$6,299,224. Net change in cash: +$2,899,123. Cash and cash equivalents at period end: $4,093,073. Cash burn from operations remains the dominant liquidity consideration.
- Balance sheet health: Total assets $5,007,718; total current assets $4,766,742; cash and equivalents $4,093,073. Total current liabilities $1,254,750; no long-term debt reported. Retained earnings stand at -$56,410,033, underscoring substantial cumulative losses to date. Total stockholders’ equity $3,752,968. Current ratio 3.80, quick ratio 3.80, cash ratio 3.26, indicating a solid short-term liquidity buffer despite ongoing cash burn.
- Valuation snapshot: Price-to-book ~13.30x, enterprise value multiples negative, and negative earnings yield reflect early-stage, pre-revenue status. These multiples imply high risk but potential upside if the AL001 program milestones resonate with the market.